𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: Results from a controlled randomized trial in 80 patients*1

✍ Scribed by BOUCHER, E

Book ID
122931946
Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
761 KB
Volume
21
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Interferon and ursodeoxycholic acid comb
Interferon and ursodeoxycholic acid combined therapy in the treatmet of chronic viral C hepatitis: Results from a controlled randomized trial in 80 patients
✍ Eveline Boucher; HervΓ© Jouanolle; Patrice Andre; Annick Ruffault; Dominique Guya πŸ“‚ Article πŸ“… 1995 πŸ› John Wiley and Sons 🌐 English βš– 744 KB

Because 70% to 75% of patients with chronic hepatitis C either do not respond to or relapse after interferon (IFN) therapy, and because ursodeoxycholic acid (UDCA) has been shown to reduce aminotransferase lev-TOLOGY 199% 21 :322-327.

Combination therapy with thymosin Ξ±1 and
Combination therapy with thymosin Ξ±1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double-blind trial
✍ Kenneth E. Sherman; Maria Sjogren; Robin L. Creager; Melissa A. Damiano; Stephen πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 111 KB πŸ‘ 1 views

Hepatitis C is a major cause of liver disease leading to cirrhosis. Although interferon (IFN) is the only approved therapy, treatment is characterized by low response rates and dose-limiting side effects. We evaluated the addition of thymosin ␣1 (TA1), an immunomodulatory peptide, to the standard tr